Mizzen Capital has provided term loan financing to The Company, a healthcare trade school, to support its expansion and development of educational programs amid growing demand in the healthcare sector.
Information on the Target
The Company is a prominent healthcare trade school that specializes in providing high-quality training and educational services to future healthcare professionals. Their comprehensive programs include in-person instruction, lab skill development, and practical hands-on experiences at hospitals and healthcare facilities. Many graduates have successfully embarked on careers within the healthcare sector, underscoring the Company's effectiveness in preparing students for the demands of this vital industry.
Dedicated to excellence, The Company offers a range of programs in critical areas such as Diagnostic Medical Sonography, Radiography, Radiation Therapy, Surgical Technology, Medical Dosimetry, as well as Paramedic and EMT certification. By combining rigorous training with state-of-the-art facilities, the Company ensures that its students are well-equipped to meet the challenges of their chosen professions.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The healthcare education sector plays a critical role in developing a skilled workforce capable of addressing the growing healthcare needs of the population. With increasing demand for healthcare services, particularly in critical care and eme
Similar Deals
Alantes Corporate Finance → Center for Serving Leadership
2025
Alantes Corporate Finance, LLC → Appcompanist, LLC
2024
Meharry Medical College Ventures Inc. → Heal90 Inc.
2024
Graycliff Partners LP → Guidewell Education
o15 Capital Partners → Simplify Compliance Holdings, LLC
Caltius Structured Capital → Strategic Kids, LLC
Mizzen Capital
invested in
Healthcare Trade School
in 2024
in a Venture Debt deal